Publications by authors named "A A Argyriou"
Hypoxia inducible factor 2α (HIF-2α) is a member of the basic helix-loop-helix(bHLH)-Per-Arnt-Sim (PAS) family of transcription factors. It is overexpressed in several cancers, associated with poor prognosis of the patients and resistance to treatment. Here, we study the residues 366-704 of the C-terminal end of human HIF-2α, which contains the N-transcriptional activation domain (NTAD), the oxygen-dependent degradation domain (ODD), and a part of the inhibitory domain (IH).
View Article and Find Full Text PDFBackground And Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is perceived differently by patients and physicians, complicating its assessment. Current recommendations advocate combining clinical and patient-reported outcomes measures, but this approach can be challenging in patient care. This multicenter European study aims to bridge the gap between patients' perceptions and neurological impairments by aligning both perspectives to improve treatment decision-making.
View Article and Find Full Text PDFObjective: This post-hoc analysis of data extracted from a prospective study aimed to explore for the first time if the efficacy of fremanezumab in preventing difficult-to-treat migraine, according to ICHD-III, would differ between pre-menopausal and post-menopausal women.
Methods: A total of 171 (aged 18-70 years) fremanezumab-treated female migraine patients for six consecutive months were classified to those at pre-menopausal ( = 82) or post-menopausal ( = 89). Monthly headache days (MHD), disability, and quality of life (QOL) outcomes were assessed at baseline and at week 24 post-fremanezumab within subgroups and were then compared between them.
Article Synopsis
- Researchers aimed to assess if plasma neurofilament light chain (pNfL) levels can act as a real-time biomarker for chemotherapy-induced peripheral neurotoxicity (CIPN) across different chemotherapy drugs.
- The study involved 82 patients receiving treatments (paclitaxel, brentuximab vedotin, or oxaliplatin) and evaluated their pNfL levels, Neuropathy Scores, and nerve conduction studies before, during, and after treatment.
- Results indicated that all groups experienced increased pNfL levels during treatment, but those on paclitaxel showed significantly greater and earlier changes, suggesting the need for specific pNfL threshold values tailored for different chemotherapy agents.
Background: To identify the preferences and perceptions of migraine patients for acute and preventive treatment options and to investigate which treatment outcomes are the most important.
Design And Methods: The authors performed a choice-format survey in a cohort of migraine patients from Greece and Cyprus. A self-administered questionnaire developed in collaboration with the Greek Society of Migraine Patients was used.